elecell Co., Ltd., developer of treatment bandages for diabetic conditions and chronic wounds, has been selected for the fast track of the Deep Tech TIPS program.

elecell, an innovative startup developing medical devices for chronic wound treatment based on electrical stimulation, recently secured a fast track selection in the Deep Tech TIPS (Private Investment-led Technology Startup Support Program) organized by the Ministry of SMEs and Startups. The Deep Tech TIPS program supports innovative startups based on advanced technologies by providing up to 1.7 billion KRW in R&D funding for companies that have received more than 0.3 billion KRW in private investments.

elecell, founded in March 2024, participated in Synergy IB Investment’s 'SYNERGY TIPS Linked Startup 1st Batch,' an early-stage venture nurturing program run by a new technology financing company. Through this program, elecell successfully secured investments and entered the Deep Tech TIPS program. Recognized for its outstanding technological capabilities and market potential in the first evaluation, the company was fast-tracked by being exempted from the second evaluation.

elecell’s CEO, Hyung-Seop Han, is currently serving as a principal researcher at KIST (Korea Institute of Science and Technology) under the entrepreneurship leave system, using KIST-developed technology to lead the company. elecell has developed a chronic wound treatment device that treats conditions such as diabetic foot ulcers, pressure sores, and burns by combining groundbreaking technologies, including a biomimetic transpiration-based renewable energy technology and reactive oxygen species removal materials. The company is now accelerating efforts to obtain approval from the Ministry of Food and Drug Safety (MFDS) through collaboration with top-tier domestic research institutions and advanced general hospitals. The technology is expected to set a positive precedent by applying KIST’s foundational research outcomes to the bio-industry, having been developed with the support of KIST’s major research projects.

Additionally, elecell plans to commercialize an electrical stimulation-based cell activation platform technology to prevent sarcopenia, which has demonstrated excellent results in preventing sarcopenia and improving walking function in recent animal experiments conducted at Seoul Asan Medical Center's Neurosurgery Research Lab.

CEO Hyung-Seop Han of elecell stated, “The Deep Tech TIPS project marks an important first step toward realizing elecell’s vision. We will do our best to expedite the commercialization of our new technology by applying for the designation of innovative medical devices and successfully entering the global market.”

elecell expressed its strong determination to commercialize innovative biomedical technologies, providing solutions for patients suffering from injuries, diseases, and chronic conditions. The company also announced that it is preparing for the next round of investment to accelerate its business expansion.

Link to original article:

https://n.news.naver.com/article/277/0005488835?sid=101